{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:10:48Z","timestamp":1787069448564,"version":"build-2736575974"},"reference-count":98,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Immunotherapy with chimeric antigen receptor T (CAR-T) cell therapies has brought substantial improvement in clinical outcomes in patients with relapsed\/refractory B cell neoplasms. However, complications such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) limit the therapeutic efficacy of this treatment approach. ICANS can have a broad range of clinical manifestations, while various scoring systems have been developed for its grading. Cognitive decline is prevalent in CAR-T therapy recipients including impaired attention, difficulty in item naming, and writing, agraphia, and executive dysfunction. In this review, we aim to present the diagnostic methods and tests that have been used for the recognition of cognitive impairment in these patients. Moreover, up-to-date data about the duration of cognitive impairment symptoms after the infusion are presented. More research on the risk factors, pathogenesis, preventive measures, and therapy of neurocognitive impairment is crucial for better outcomes for our patients.<\/jats:p>","DOI":"10.3390\/ph17050591","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T15:05:01Z","timestamp":1715007901000},"page":"591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb"],"prefix":"10.3390","volume":"17","author":[{"given":"Evlampia","family":"Strongyli","sequence":"first","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-5111","authenticated-orcid":false,"given":"Paschalis","family":"Evangelidis","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Sakellari","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-0063","authenticated-orcid":false,"given":"Maria","family":"Gavriilaki","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"},{"name":"Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T Cell Therapy: Current Limitations and Potential Strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"De Marco, R.C., Monzo, H.J., and Ojala, P.M. (2023). CAR T Cell Therapy: A Versatile Living Drug. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076300"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/BLCTT.S327016","article-title":"CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1385052","DOI":"10.3389\/fmed.2024.1385052","article-title":"Hematology: The Specialty with a Record Number of New Approvals","volume":"11","author":"Gavriilaki","year":"2024","journal-title":"Front. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., Sakellari, I., Gavriilaki, M., and Anagnostopoulos, A. (2020). A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113886"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., Dolgyras, P., Dimou-Mpesikli, S., Poulopoulou, A., Evangelidis, P., Evangelidis, N., Demosthenous, C., Zachrou, E., Siasios, P., and Mallouri, D. (2023). Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis. Cancers, 15.","DOI":"10.3390\/cancers15133529"},{"key":"ref_7","first-page":"2460","article-title":"How I Treat Cytopenias after CAR T-Cell Therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3389\/fonc.2020.00885","article-title":"Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective","volume":"10","author":"Sievers","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/bloodadvances.2022009578","article-title":"Impact of SARS-CoV-2 Vaccination and Monoclonal Antibodies on Outcome Post-CD19-Directed CAR T-Cell Therapy: An EPICOVIDEHA Survey","volume":"7","author":"Marchesi","year":"2023","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-med-061119-015600","article-title":"V Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity","volume":"72","author":"Schmidts","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological Updates: Neurological Complications of CAR-T Therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103126","DOI":"10.1016\/j.jaut.2023.103126","article-title":"Cognition Following Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review","volume":"140","author":"Kazzi","year":"2023","journal-title":"J. Autoimmun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of Neurological Toxicity in Patients Treated with Tisagenlecleucel in the JULIET Trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_16","unstructured":"(2024, March 27). YESCARTA\u00ae (Axicabtagene Ciloleucel). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/yescarta-epar-medicine-overview_en.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Pinto, S.N., and Krenciute, G. (2024). The Mechanisms of Altered Blood-Brain Barrier Permeability in CD19 CAR T-Cell Recipients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010644"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T Cell-Associated Neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"947648","DOI":"10.3389\/fimmu.2022.947648","article-title":"Cytokines as an Important Player in the Context of CAR-T Cell Therapy for Cancer: Their Role in Tumor Immunomodulation, Manufacture, and Clinical Implications","volume":"13","author":"Silveira","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF Inhibition Reduces Cytokine Release Syndrome and Neuroinflammation but Enhances CAR-T Cell Function in Xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41421-021-00255-4","article-title":"CRISPR-Edited CART with GM-CSF Knockout and Auto Secretion of IL6 and IL1 Blockers in Patients with Hematologic Malignancy","volume":"7","author":"Yi","year":"2021","journal-title":"Cell Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.4049\/jimmunol.0903732","article-title":"Differential Roles for Endothelial ICAM-1, ICAM-2, and VCAM-1 in Shear-Resistant T Cell Arrest, Polarization, and Directed Crawling on Blood\u2013Brain Barrier Endothelium","volume":"185","author":"Steiner","year":"2010","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10318","DOI":"10.1182\/blood-2022-167688","article-title":"ZUMA-19: A Phase 1\/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma","volume":"140","author":"Oluwole","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.4049\/jimmunol.161.5.2457","article-title":"IFN-Gamma Inhibits Activation-Induced Expression of E- and P-Selectin on Endothelial Cells","volume":"161","author":"Melrose","year":"1998","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/brain\/awab083","article-title":"The Hedgehog Pathway Suppresses Neuropathogenesis in CD4 T Cell-Driven Inflammation","volume":"144","author":"Benallegue","year":"2021","journal-title":"Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol. R Neuroimmunol. Neuroinflammation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-Derived IL-1 and IL-6 Are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity Due to CAR T Cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor\u2013Modified T-Cell Therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX Predicts Severe Cytokine Release Syndrome and Neurotoxicity after Chimeric Antigen Receptor T Cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1182\/blood-2023-179506","article-title":"Easix Indices Predict CRS and Overall Survival in Adult CAR-T Cell Recipients","volume":"142","author":"Gavriilaki","year":"2023","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2017.35.15_suppl.7024","article-title":"Baseline and Early Post-Treatment Clinical and Laboratory Factors Associated with Severe Neurotoxicity Following 19-28z CAR T Cells in Adult Patients with Relapsed B-ALL","volume":"35","author":"Park","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (Axi-Cel; KTE-C19) Treatment for Patients with Refractory, Aggressive Non-Hodgkin Lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of Neurotoxicity in a Series of Patients Treated with CAR T-Cell Therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL Patients Treated with CD19 CAR T Cells Experience a High Burden of Organ Toxicities but Low Nonrelapse Mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jnen\/nly064","article-title":"Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema","volume":"77","author":"Torre","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1097\/HS9.0000000000000733","article-title":"CAR T-Cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-Transplant Lymphoproliferative Disorder of the CNS","volume":"6","author":"Bink","year":"2022","journal-title":"Hemasphere"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3324\/haematol.2020.259952","article-title":"Acute Leucoencephalomyelopathy and Quadriparesis after CAR T-Cell Therapy","volume":"106","author":"Nair","year":"2021","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Li, C., Zhang, Y., Zhang, C., Chen, J., Lou, X., Chen, X., Kang, L., Xu, N., Li, M., and Tan, J. (2019). Comparation of CART19 and Autologous Stem-Cell Transplantation for Refractory\/Relapsed Non-Hodgkin\u2019s Lymphoma. JCI Insight, 5.","DOI":"10.1172\/jci.insight.130195"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Levine, J.E., Grupp, S.A., Pulsipher, M.A., Dietz, A.C., Rives, S., Myers, G.D., August, K.J., Verneris, M.R., Buechner, J., and Laetsch, T.W. (2021). Pooled Safety Analysis of Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia. J. Immunother. Cancer, 9.","DOI":"10.1136\/jitc-2020-002287"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.bbmt.2020.07.031","article-title":"Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score","volume":"26","author":"Herr","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and Management of CAR-T Neurotoxicity in Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel in CARTITUDE Studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"902301","DOI":"10.3389\/fonc.2022.902301","article-title":"Sodium Oligomannate Combined with Rivastigmine May Improve Cerebral Blood Flow and Cognitive Impairment Following CAR-T Cell Therapy: A Case Report","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-021-00166-5","article-title":"Neurological Management and Work-up of Neurotoxicity Associated with CAR T Cell Therapy","volume":"4","author":"Bonda","year":"2022","journal-title":"Neurol. Res. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e16174","DOI":"10.1111\/ene.16174","article-title":"Patterns of Neurotoxicity among Patients Receiving Chimeric Antigen Receptor T-Cell Therapy: A Single-Centre Cohort Study","volume":"31","author":"Sales","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40520-021-01943-7","article-title":"The Montreal Cognitive Assessment (MoCA): Updated Norms and Psychometric Insights into Adaptive Testing from Healthy Individuals in Northern Italy","volume":"34","author":"Aiello","year":"2022","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","article-title":"Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nprot.2006.46","article-title":"The Dimensional Change Card Sort (DCCS): A Method of Assessing Executive Function in Children","volume":"1","author":"Zelazo","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/09297049.2019.1708295","article-title":"Measurement of Executive Functioning with the National Institute of Health Toolbox and the Association to Anxiety\/Depressive Symptomatology in Childhood\/Adolescence","volume":"26","author":"Kavanaugh","year":"2020","journal-title":"Child. Neuropsychol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1037\/neu0000793","article-title":"Inhibitory Control, Working Memory and Coping with Stress: Associations with Symptoms of Anxiety and Depression in Adults with Huntington\u2019s Disease","volume":"36","author":"Ciriegio","year":"2022","journal-title":"Neuropsychology"},{"key":"ref_55","unstructured":"Soto, T. (2013). Encyclopedia of Autism Spectrum Disorders, Springer."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","article-title":"Neuro-QOL: Brief Measures of Health-Related Quality of Life for Clinical Research in Neurology","volume":"78","author":"Cella","year":"2012","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.jtct.2022.05.015","article-title":"Change in Patients\u2019 Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma","volume":"28","author":"Barata","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2013.05.009","article-title":"Validating the M. D. Anderson Symptom Inventory (MDASI) for Use in Patients with Ovarian Cancer","volume":"130","author":"Sailors","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40487-021-00174-0","article-title":"Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study","volume":"10","author":"Cheng","year":"2022","journal-title":"Oncol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"254.e1","DOI":"10.1016\/j.jtct.2023.01.004","article-title":"Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T","volume":"29","author":"Akinola","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-Related Quality of Life with Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of Mid-Term (6-12 Months) Neurotoxicity in B-Cell Lymphoma Patients Treated with CAR T Cells: A Prospective Cohort Study","volume":"23","author":"Maillet","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1212\/WNL.0000000000201083","article-title":"Long-Term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"99","author":"Ursu","year":"2022","journal-title":"Neurology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1080\/13854046.2019.1585574","article-title":"Wechsler Adult Intelligence Scale-4th Edition Digit Span Performance in Subjective Cognitive Complaints, Amnestic Mild Cognitive Impairment, and Probable Dementia of the Alzheimer Type","volume":"33","author":"Ruchinskas","year":"2019","journal-title":"Clin. Neuropsychol."},{"key":"ref_68","unstructured":"Wambach, D., Lamar, M., Swenson, R., Penney, D.L., Kaplan, E., and Libon, D.J. (2011). Encyclopedia of Clinical Neuropsychology, Springer."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/WAD.0b013e3181cfc78b","article-title":"Free and Cued Selective Reminding Identifies Very Mild Dementia in Primary Care","volume":"24","author":"Grober","year":"2010","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jalz.2016.12.014","article-title":"Free and Cued Selective Reminding Test-Accuracy for the Differential Diagnosis of Alzheimer\u2019s and Neurodegenerative Diseases: A Large-Scale Biomarker-Characterized Monocenter Cohort Study (ClinAD)","volume":"13","author":"Teichmann","year":"2017","journal-title":"Alzheimers Dement."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09658210244000027","article-title":"The Prospective and Retrospective Memory Questionnaire (PRMQ): Normative Data and Latent Structure in a Large Non-Clinical Sample","volume":"11","author":"Crawford","year":"2003","journal-title":"Memory"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1073191115602552","article-title":"The Trail Making Test","volume":"24","year":"2017","journal-title":"Assessment"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/nprot.2006.390","article-title":"Administration and Interpretation of the Trail Making Test","volume":"1","author":"Bowie","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_74","unstructured":"Ciolek, C.H., and Lee, S.Y. (2020). Guccione\u2019s Geriatric Physical Therapy, Elsevier."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"564647","DOI":"10.3389\/fimmu.2020.564647","article-title":"Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5014\/ajot.44.7.589","article-title":"An Overview of Sensory Integration and Praxis Tests","volume":"44","author":"Mailloux","year":"1990","journal-title":"Am. J. Occup. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1148\/123.3.653","article-title":"Cranial Computed Tomography in Aphasia. Correlation of Anatomical Lesions with Functional Deficits","volume":"123","author":"Hayward","year":"1977","journal-title":"Radiology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1532-5415.1992.tb01992.x","article-title":"The Mini-Mental State Examination: A Comprehensive Review","volume":"40","author":"Tombaugh","year":"1992","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_79","first-page":"CD011145","article-title":"Mini-Mental State Examination (MMSE) for the Detection of Dementia in Clinically Unevaluated People Aged 65 and over in Community and Primary Care Populations","volume":"2016","author":"Creavin","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s11682-022-00698-7","article-title":"Semantic Fluency Deficits and Associated Brain Activity in Parkinson\u2019s Disease with Mild Cognitive Impairment","volume":"16","author":"Yang","year":"2022","journal-title":"Brain Imaging Behav."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3758\/s13428-020-01467-4","article-title":"MULTIMAP: Multilingual Picture Naming Test for Mapping Eloquent Areas during Awake Surgeries","volume":"53","author":"Amoruso","year":"2021","journal-title":"Behav. Res. Methods"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"305.e1","DOI":"10.1016\/j.jtct.2022.03.023","article-title":"Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy","volume":"28","author":"Hoogland","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/87565641.2021.1951270","article-title":"Examining Conners Continuous Performance Test-3 (CPT-3) Embedded Performance Validity Indicators in an Adult Clinical Sample Referred for ADHD Evaluation","volume":"46","author":"Scimeca","year":"2021","journal-title":"Dev. Neuropsychol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Clinical Validity","volume":"20","author":"Randolph","year":"1998","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"241674","DOI":"10.3389\/fpsyg.2017.00557","article-title":"The Stroop Color and Word Test","volume":"8","author":"Scarpina","year":"2017","journal-title":"Front. Psychol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/09084282.2010.499787","article-title":"Validity of the Wechsler Test of Adult Reading (WTAR): Effort Considered in a Clinical Sample of U.S. Military Veterans","volume":"17","author":"Whitney","year":"2010","journal-title":"Appl. Neuropsychol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-12-811161-1.00012-8","article-title":"Neurocognitive Aspects of Brain Metastasis","volume":"149","author":"Wefel","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s41687-018-0071-4","article-title":"Important Differences and Meaningful Changes for the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)","volume":"2","author":"Bell","year":"2018","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1590\/1980-57642016dn11-020005","article-title":"Utility of the Neuropsychiatric Inventory Questionnaire (NPI-Q) in the Assessment of a Sample of Patients with Alzheimer\u2019s Disease in Chile","volume":"11","author":"Musa","year":"2017","journal-title":"Dement. Neuropsychol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","article-title":"A Phase 1 Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-Cell Lymphoma","volume":"7","author":"Strati","year":"2023","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1182\/bloodadvances.2023009961","article-title":"A Phase 2 Trial of Defibrotide for the Prevention of Chimeric Antigen Receptor T-Cell\u2013Associated Neurotoxicity Syndrome","volume":"7","author":"Jacobson","year":"2023","journal-title":"Blood Adv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1182\/bloodadvances.2023011027","article-title":"ICANS Prophylaxis: Potentially Transformative but Elusive","volume":"7","author":"Dowling","year":"2023","journal-title":"Blood Adv."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Mavrikou, I., Chatzidimitriou, D., Skoura, L., Nikolousis, E., Sakellari, I., and Gavriilaki, E. (2023). Molecular Advances in Sinusoidal Obstruction Syndrome\/Veno-Occlusive Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065620"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40520-023-02361-7","article-title":"Association between Ambulatory Blood Pressure Monitoring Patterns with Cognitive Function and Risk of Dementia: A Systematic Review and Meta-Analysis","volume":"35","author":"Gavriilaki","year":"2023","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/09612033231167792","article-title":"Depression in Systemic Lupus Erythematosus: A Manifestation of Microcirculation Dysfunction?","volume":"32","author":"Koletsos","year":"2023","journal-title":"Lupus"},{"key":"ref_96","first-page":"197","article-title":"Evidence of Endothelial Dysfunction in the Development of Alzheimer\u2019s Disease: Is Alzheimer\u2019s a Vascular Disorder?","volume":"3","author":"Kelleher","year":"2013","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"452.e1","DOI":"10.1016\/j.jtct.2024.01.063","article-title":"Quality of Life and Prognostic Awareness in Caregivers of Patients Receiving Chimeric Antigen Receptor T Cell Therapy","volume":"30","author":"Barata","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Liang, E.C., Rejeski, K., Fei, T., Albittar, A., Huang, J.J., Portuguese, A.J., Wu, Q., Raj, S., Subklewe, M., and Shouval, R. (2024). Development and Validation of an Automated Computational Approach to Grade Immune Effector Cell-Associated Hematotoxicity. Bone Marrow Transplant.","DOI":"10.1038\/s41409-024-02278-3"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/5\/591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:40:32Z","timestamp":1760107232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/5\/591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":98,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ph17050591"],"URL":"https:\/\/doi.org\/10.3390\/ph17050591","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}